Citius Pharmaceuticals Inc vs eBay Inc — how do they compare? Citius Pharmaceuticals Inc trades at $0.49 (market cap $13.62M), while eBay Inc trades at $111.7 (market cap $49.83B). The key difference: eBay Inc is far larger — about 3658.6× Citius Pharmaceuticals Inc's market cap, and eBay Inc pays a 1.11% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 16 Days and eBay Inc for 134 Days on average.
| CTXR | EBAY | |
|---|---|---|
Market Cap | $13.62M | $49.83B |
Volume | 132,438 | 2,986,953 |
Sector | Health | Consumer Cyclical |
52-Week High | $1.82 | $118.96 |
52-Week Low | $0.48 | $79.41 |
Typical Hold Time | 16 Days | 134 Days |
Enterprise Value | $3.79M | $53.65B |
Dividend Yield | — | 1.11% |
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.5082, up 5.72% today, but remains in a bearish technical trend with negative profitability metrics. The company reported $7.1M revenue for the first nine months of 2026 from LYMPHIR sales, though net income margin remains deeply negative at -651.27%. Analyst consensus is strongly bullish with 5 buy ratings and a $5.00 price target, representing significant upside potential from current levels.
While CTXR shows promising commercial progress with its oncology drug launch, the stock faces substantial execution risks due to persistent losses and cash burn. The bullish analyst sentiment contrasts with weak fundamentals, creating a high-risk, high-reward scenario for investors betting on successful commercialization of LYMPHIR in the $400M+ CTCL market.
EBAY trades at $107.60, up 0.5% with a bullish technical signal and strong recent earnings beats. The company maintains robust profitability with 72% gross margins and 18.6% net income margin, though revenue growth remains moderate. Analyst consensus is positive with a $117.68 price target, representing 9% upside potential. Recent news highlights strategic focus on collectibles and live commerce while navigating competitive pressures from Amazon's multi-platform seller tools.
EBAY presents a balanced opportunity with strong fundamentals and analyst support, though faces execution risks in growth initiatives and competitive threats. The stock's current valuation appears reasonable given earnings consistency, but investors should monitor advertising growth trends and GameStop's strategic stake in the company.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →eBay Inc. is a global commerce company. The Company's platforms are designed to enable sellers worldwide to organize and offer their inventory for sale and buyers to find and buy it. eBay's items can be new or used, plain or luxurious, commonplace or rare, trendy or one-of-a-kind.
Read more on EBAY →